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Abstract  This  paper  aims  to  argue  the  advantages  of  using  routine  multiparametric  MRI  (mp-
MRI) prior  to  the  ﬁrst  series  of  biopsies  in  patients  with  suspected  cancer  of  the  prostate
indicated  by  a  rise  in  Prostatic  Speciﬁc  Antigen  (PSA).  Using  biopsy  targeted  onto  a  lesion  seen
by MRI,  this  diagnostic  strategy  could  increase  detection  of  signiﬁcant  cancers  and  improve
evaluation  of  their  grade  and  size.  This  strategy  would  also  mean  that  the  detection  of  insignif-
icant cancers  (microfoci  detected  by  chance  during  systematic  biopsy)  would  decrease,  since
if the  mp-MRI  did  not  give  rise  to  suspicion,  the  indications  for  biopsy  would  be  reduced.  It
could also  reduce  the  number  of  biopsies  to  be  performed  even  when  the  mp-MRI  is  suspicious,
by resorting  solely  to  targeted  biopsies.  This  review  does  not  evaluate  the  role  of  mp-MRI  in
locoregional  staging.
© 2012  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
The  traditional  diagnostic  strategy  for  cancer  of  the  prostate,  based  on  a  thresh-
old  Prostatic  Speciﬁc  Antigen  (PSA)  value  along  with  performing  systematic  transrectal
ultrasound-guided  biopsy  (12  biopsies  sampling  the  17  mm  of  the  posterior  part  of  the
gland),  is  associated  with  diagnostic  errors.  This  method  is  indeed  producing  over-diagnosis
of  clinically  insigniﬁcant  cancers  and  failing  to  detect  certain  cancers,  which  are  clinically
signiﬁcant.  There  are  in  fact  (anterior)  areas  of  the  prostate  gland  that  are  not  sampled
by  systematic  standard  biopsies,  even  with  the  extended  plan,  which  makes  the  results  of
them  unreliable.An  alternative  to  this  traditional  strategy  is  to  add  multiparametric  MRI  (mp-MRI)  to
biopsy  or  to  substitute  it  for  the  latter,  thus  providing  the  best  diagnostic  sequence.  Mp-
MRI  is  an  accessible  imaging  technique,  but  performing  it,  interpreting  it  and  evaluating
it  require  considerable  expertise  [1].  One  of  the  arguments  in  favour  of  using  pre-biopsy
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Figure 1. Standard scheme of 27 zones for locating suspect
lesions seen on MRI. Sections of the base, the middle and the apex
of the prostate. Sagittal and frontal section. Each section is subdi-
vided into four posterior regions (p) (mid-lobar and lateral), four
anterior regions (a) (mid lobar and lateral) and three regions of the
anterior stroma (as), in the centre, in front of the glandular zones.
The standard 12 biopsy plan samples the 12 posterior regions, 17 mm
anteroposteriorly. VS: seminal vesicles.
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[MRI  with  prostate  biopsy:  The  clinician’s  point  of  view  
mp-MRI  is  based  on  the  principle  of  guiding  biopsies  accord-
ing  to  abnormalities  seen  on  imaging,  rather  than  mapping
from  a  pre-established  diagram  of  part  of  the  gland.  This
principle,  of  performing  biopsies  targeted  on  abnormalities
detected  clinically  or  on  imaging,  is  the  norm  for  all  solid
organs.
The  economic  impact  of  performing  an  mp-MRI  in  all  men
in  whom  a  prostate  biopsy  is  indicated  should  be  evaluated.
Pre-biopsy  mp-MRI  naturally  implies  adapting  resources,
both  in  terms  of  staff  and  of  equipment,  and  requires  initial
investment.
Pre-biopsy mp-MRI improves identiﬁcation
and  characterisation of cancer of the
prostate
Mp-MRI  is  effective  for  studying  the  anterior  and  posterior
regions  of  the  prostate  in  patients  presenting  lesions  sus-
pected  of  being  neoplastic.
A European  consensus  group  of  MRI  experts  recently
recommended  that  this  modern  imaging  technique  should
be  performed  as  an  examination  prior  to  biopsy  [1].  It
is  however  necessary  for  the  MRI  to  be  performed  in  a
standard  way  in  all  centres.  The  experts  agreed  on  67%
of  the  260  items  related  to  the  imaging  sequences  nec-
essary,  and  decided  for  example,  that  the  MRI  sequences
necessary  are  T2-weighted,  dynamic  T1  contrast-enhanced
and  diffusion-weighted  sequences,  whereas  spectroscopy  is
not  recommended.  The  experts  also  agreed  on  54%  of  the
260  issues  concerning  interpreting  the  images.  At  least  16
and  up  to  27  prostate  zones  where  cancer  may  occur  must
be  described  (Fig.  1.)  A  suspected  cancer  scale  from  1  to  5
was  approved  to  harmonise  communication  in  describing  the
lesions  observed.  Because  of  increase  in  the  signal-to-noise
ratio,  3  Tesla  MRI  decidedly  improves  spatial,  temporal  and
spectral  resolution  of  the  prostate  in  all  imaging  sequences.
Nevertheless,  1.5  Tesla  with  a  pelvic  coil  can  be  used  to
provide  interpretation  of  the  signals  observed  in  suspect
areas  that  is  similar  to  3  T  MRI.  It  has,  indeed,  been  decided
that  this  use  of  1.5  T  MRI  with  a  pelvic  coil  is  adequate
for  standard  clinical  practice.  An  endorectal  coil  is  no
longer  necessary  for  performing  prostate  MRI  to  detect  can-
cer.
Mp-MRI  is  very  sensitive  and  speciﬁc  for  detecting
anterior  and  posterior  cancers  [2—5]. It  has  been  shown
that  for  a  volume  greater  than  0.5  cm3,  sensitivity  and
speciﬁcity  are  86%  and  94%,  respectively.  The  negative  pre-
dictive  value  is  95%.  The  mean  volume  of  cancers  detected
using  MRI  is  2.44  mL  (0.02—14.5)  and  the  mean  volume
of  lesions  not  detected  by  MRI  is  0.16  mL  (0.01—2.4).
For  tumours  larger  than  0.2  cm3,  there  is  good  corre-
lation  between  assessment  of  the  tumour  volume  using
T1-weighted  dynamic  MRI  with  injection  of  gadolinium  and
the  tumour  volume  found  from  histopathological  analysis  of
ablated  tissue.
Functional  imaging  techniques  help  characterise  the  can-
cer  (Fig.  2).  The  degree  of  enhancement  on  the  T1  sequences
with  injection  of  gadolinium  and  restriction  of  diffusion,
for  example,  seem  to  be  related  to  the  Gleason  score
[6—8].
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he role of pre-biopsy MRI with targeted
iopsies
urrent diagnostic strategy based on
ystematic biopsy
ith  the  current  strategy,  the  real  grade  of  the  tumour  is
nderestimated  in  a  third  of  cases  and  the  extent  under-
stimated  in  more  than  50%  of  the  patients  whose  tumour
s  low  risk  [9].  Consequently,  locating  an  individual  tumour
ocus  in  the  prostate  is  rather  unlikely,  whereas  the  sensi-
ivity  of  mp-MRI  for  detecting  anterior  and  posterior  cancers
s  high.  Recent  publications  have  therefore  backed  the  idea
f  targeted  biopsy.
Current  practice  is  still  to  take  ten  to  12  transrectal
ltrasound-guided  biopsies  following  a  standard  plan.
ndorectal  ultrasonography  is  used  to  deﬁne  the  contours
f  the  prostate  gland  and,  to  a  lesser  degree,  to  guide  the
iopsies.  Sampling  is  therefore  done  randomly,  the  operator
ften  not  having  any  idea  of  the  location  of  tumorous  areas
f  no  suspect  lesions  can  be  seen  on  the  ultrasound  image.
n  addition,  these  biopsies  are  basically  concerned  with  the
eripheral  area;  sampling  the  anterior  and  transition  areas  is
nadequate  [10], whereas  it  has  been  shown  that  when  biop-
ies  are  guided  to  the  anterior  apex,  detection  is  increased
11].  One  of  the  possible  ways  of  overcoming  this  sampling
nadequacy  is  to  increase  the  number  of  biopsies.  However,
ransrectal  ultrasound-guided  saturation  biopsy  strategies
ave  not  been  found  to  be  advantageous  in  this  context.
ransperineal  mapping  biopsies  (40  to  50  samples),  with  a
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Figure 2. Multiparametric 1.5 T MRI with pelvic coil. Axial slices at the junction of the inferior 1/3 with the middle 1/3: a: T2-weighted
sequence. Suspect lesion in T2 hyposignal affecting the right transition area and the right anterolateral strip of the peripheral area, measuring
16 mm across its largest diameter. No signs of extraprostatic extension; b: diffusion map: very suspect lesion with strong diffusion restriction
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at the location of the lesion previously described; c: dynamic seque
ubtraction, at T= 30 s: very suspect lesion, with intense hypersigna
lacement  grid,  have  not  been  reported  in  the  experience
f  French  centres.
he mp-MRI/guided biopsy combination
his  combination  improves  biopsy  performance  by  increas-
ng  detection  of  signiﬁcant  cancers,  reducing  detection  of
nsigniﬁcant  cancers  and  allowing  better  sampling  (core
ength  and  cancer  grade  from  the  biopsies).  The  result  is
mproved  evaluation  and  therefore,  a  more  accurate  prog-
osis.  This  would  also  mean  that  the  number  of  biopsies  per
atient  could  be  reduced.  For  example,  a  great  many  cen-
res  have  independently  reported  detection  rates,  in  men
ith  suspected  cancer  of  the  prostate  and  a  ﬁrst  series  of
egative  biopsies,  that  vary  from  30%  to  59%  (mostly  anterior
ancers),  by  using  biopsies  targeted  on  lesions  detected  by
RI  [12—17]. In  addition,  assessment  of  the  size  and  grade  of
he  tumours  were  improved  by  44%  using  guided  biopsy,  com-
ared  with  systematic  biopsy  [18]. It  has  also  been  shown
hat  targeting  biopsies  uniquely  on  lesions  detected  by  MRI  is
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hith subtraction, at T0; d: MRI of prostate: dynamic sequence with
m the area already described.
ore  effective  for  detecting  signiﬁcant  cancers  than  system-
tic  transrectal  ultrasound-guided  biopsy.  It  is  associated
ith  less  detection  of  insigniﬁcant  cancers  and  less  biopsies
verall  and  per  patient  [19]. Biopsies  targeted  on  areas  that
ppear  suspect  on  MR  images  improve  detection  of  anterior
ancers  (which  are  located  beyond  the  area  sampled  by  pos-
erior  biopsies).  These  anterior  cancers  make  up  20%  of  the
igniﬁcant  cancers  in  an  unscreened  population  of  patients
uspected  of  having  prostate  cancer  [18].
he role of targeted biopsy without
ystematic  biopsy
his  was  studied  retrospectively  in  a series  of  555  men  with
aised  PSA  [19]. Mp-MRI  was  positive  in  351  patients  (63%),
nd  302  patients  (54%)  had  a  cancer  detected  at  the  time  of
ystematic  and/or  guided  biopsy.  This  54%  detection  rate  is
onsistent  with  the  average  detection  rate  of  50%  observed
n  a  European  population  of  newly  screened  patients  with  no
istory  of  biopsy  and  a  mean  PSA  level  of  6.75.  The  rate  of
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detection  of  signiﬁcant  cancers  of  the  prostate  was  higher
by  guided  biopsy  than  by  systematic  biopsy  (p  <  0.01)  and
the  quality  of  the  sampling  was  better  than  with  systematic
biopsy.  In  a  series  of  cancers  irrespective  of  location,  the
mean  length  of  invasion  of  targeted  biopsies  was  5.56  mm
as  against  4.70  mm  for  systematic  biopsies  (p  =  0.018).
In  a  study  of  46  anterior  cancers,  the  mean  invasion  of
targeted  biopsies  was  8  mm  compared  with  1  mm  for  system-
atic  biopsies  (p  <  0.001)  [18]. In  addition,  targeted  biopsies
helped  detect  higher  grade  tumours,  with  respectively  16%
more  grade  4  or  5  cancers  compared  with  all  location  sys-
tematic  biopsies  and  44%  for  anterior  cancers  [18,19].
These  results  demonstrate  the  role  of  pre-biopsy  mp-MRI
associated  with  targeted  biopsy.
Not  only  does  MRI  detect  intraprostatic  targets  towards
which  biopsies  can  be  directed,  but  because  of  MRI,  per-
forming  a  biopsy  in  men  with  a  low  probability  of  having
a  clinically  signiﬁcant  cancer  can  be  deferred.  For  signiﬁ-
cant  cancers  Mp-MRI  indeed  has  a  negative  predictive  value
greater  than  90%.  It  could  therefore  be  used  as  a  screen-
ing  examination  to  avoid  biopsy  if  it  does  not  reveal  any
abnormalities,  just  as  a  normal  mammography  result  is  used
for  not  biopsying  women  whose  risk  of  having  breast  can-
cer  is  low.  In  cooperation  with  the  team  from  Cleveland,
we  demonstrated  in  this  study  the  potential  beneﬁt  of  this
diagnostic  strategy  [19]. Prostate  biopsy  can  be  avoided  in
a  little  under  half  of  men  (47%)  who  have  a  non-suspect  mp-
MRI.  This  would  reduce  the  rate  of  detection  of  insigniﬁcant
cancers  by  13%,  as  has  been  shown  in  the  study  by  Rouse
et  al.  in  which  mp-MRI  was  used  for  pre-biopsy  selection
[20].  The  negative  predictive  value  of  MRI  of  94%  for  detect-
ing  cancer  is  high  enough  for  it  to  be  used  as  a  screening  test
before  biopsy  or  before  indications  for  re-biopsy,  resulting
in  a  reduction  in  the  number  of  men  requiring  several  series
of  biopsies.
This  has  already  been  described  but  has  not  yet  been
widely  accepted  by  the  urology  community.  Ahmed  et  al.
recommended  increasing  use  of  mp-MRI  before  prostate
biopsy  but  recognised  that  the  expertise  required  is  only
available  in  a  limited  number  of  centres  [21]. The  authors
also  emphasized  that  the  effectiveness  of  mp-MRI  may  be
limited  by  haemorrhagic  artefacts  if  it  is  performed  in  the
six  to  eight  weeks  following  biopsy.
Different biopsy techniques targeted on areas
seen as suspect in MRI
Ultrasound-controlled  freehand  targeted  biopsies
These  biopsies  are  easy  to  perform.  Nevertheless,  a  biopsy
targeted  on  a  suspect  area  detected  by  mp-MRI  is  not,  in  this
case,  really  guided  by  the  MRI.  A  process  of  mental  recon-
stitution  is  used  to  locate  the  suspect  area,  detected  by
mp-MRI,  on  the  ultrasound  image,  with  the  help  of  stan-
dardised  report  diagrams.
The  accuracy  of  these  biopsies  targeted  by  mental  recon-
struction  has  been  evaluated.  The  coefﬁcient  of  correlation
between  the  length  of  the  tumour  on  the  targeted  biop-
sies  (median  8  mm,  conﬁdence  interval:  7—12  mm)  and  the
greatest  anteroposterior  diameter  of  the  lesion  considered
on  mp-MRI  to  be  suspect  (median  10  mm,  conﬁdence  inter-
val  8—14  mm)  is  r2 =  0.6  (p  <  0.01)  [18]. There  are  therefore
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trong  arguments  in  favour  of  this  simple  pinpointing  tech-
ique,  based  on  the  zonal  anatomy  of  the  prostate  and  on
tandardised  reports,  in  which  two  core  biopsies  are  taken
rom  the  area  determined  as  suspect.  In  this  study,  mp-MRI
as  performed  prior  to  any  series  of  biopsies.  For  each  sus-
ect  area  (anterior  or  posterior),  2  to  4  additional  targeted
iopsies  were  taken.  Each  mp-MRI  was  simultaneously  eval-
ated  by  a  radiologist  and  a  urologist,  which  meant  that
he  urologist  could  thus  locate  the  suspect  areas  during  the
ndorectal  ultrasound.  The  targeted  biopsies  were  taken
reehand.
The  suspect  lesions  detected  by  MRI  within  the  poste-
ior  area  of  the  prostate  were  generally  associated  with
ypoechoic  areas  on  transrectal  ultrasound  images,  so  that
iopsies  could  be  better  targeted.  In  contrast,  lesions  in  the
nterior  area  could  not  be  identiﬁed  by  ultrasound  in  all
ases,  because  of  the  heterogeneity  of  the  transition  area
nd  hypoechogenicity  of  the  anterior  ﬁbromuscular  stroma.
RI-guided  biopsies  in  real  time
his  method  of  biopsy  has  also  shown  improvement  in  the
etection  of  cancer  [12—17]. In  these  studies  on  patients
ith  a  ﬁrst  series  of  negative  biopsies,  the  rate  of  detec-
ion  by  MRI-guided  biopsy  was  59%,  30%,  52%,  41%,  45.5%
nd  31.5%  respectively.  However,  such  real-time  MRI-guided
iopsy  requires  expert  teams  and  equipment  to  be  available.
using  MR  and  ultrasound  images
his  is  done  at  the  time  of  biopsy  using  virtual  navigation  in
eal  time,  with  rigid  registration,  or  by  3D  acquisition  with
on-rigid  or  elastic  registration,  and  is  currently  being  eval-
ated.  The  technique  has  proved  feasible.  [22]. It  requires
hin  slice  images  to  be  imported  with  the  location  of  the
uspect  area  clearly  identiﬁed.
p-MRI could be added to active surveillance
o replace biopsy
t  can  be  envisaged  that  mp-MRI  could  be  substituted  for
he  series  of  biopsies  performed  during  active  surveil-
ance,  completed,  if  need  be,  by  targeted  biopsies.  In  a
eta-analysis,  it  has  been  shown  that  MRI  combined  with
pectroscopy  could  be  used  in  monitoring  low  risk  patients.
his  result  needs  to  be  veriﬁed  in  larger  studies  and  the
ost/effectiveness  ratio  must  be  established  [23].
If  we  wish  to  use  imaging  as  a  patient  monitoring  tool  for
ctive  surveillance,  we  must  study  the  ability  of  this  imaging
xamination  to  predict  the  histopathological  results  of  spec-
mens  from  radical  prostatectomy.  Since  these  results  do  not
owever  always  reﬂect  the  long-term  evolution  of  the  dis-
ase,  it  would  be  preferable  to  compare  the  images  made
uring  diagnosis  with  the  long-term  results  of  the  disease,
hether  treated  or  not.  For  example,  recent  work  suggests
hat  the  values  of  the  apparent  diffusion  coefﬁcient  predict
linical  evolution  better  than  the  Gleason  score  [8].
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TAKE-HOME  MESSAGES
• Multi-parametric  MRI  is  the  only  examination  with
which  tumour  foci  in  all  areas  of  the  prostate  gland
can  be  detected  and  characterised.
• MRI as  an  addition  to  prostate  biopsies:
◦ Ultrasound-guided  prostate  biopsy  underestimates
the  grade  and  size  of  the  cancer  in  more  than  a
third  of  cases  and  samples  the  anterior  and  apical
regions  poorly.
◦ The  sensitivity  and  speciﬁcity  of  multi-parametric
MRI  performed  before  biopsy  is  respectively  86%
and  94%  for  identifying  a  cancer  of  signiﬁcant  size,
i.e.  >  0.5  cm3.  The  negative  predictive  value  is
95%.
◦ Biopsies  targeted  on  suspect  areas  detected  by  MRI
permit  better  detection  and  characterisation  of
the  size  of  the  lesion  and  the  grade  of  the  cancer.
◦ A strategy  of  biopsy  solely  targeted  on  lesions
that  appear  suspect  in  MRI,  without  associated
systematic  biopsy,  would  reduce  the  detection
of  insigniﬁcant  cancers  by  13%  and  decrease  the
number  of  biopsies  per  patient.  In  addition,  42%
of  patients  with  an  MRI  clear  of  suspicion  would
not  have  any  biopsies.
• MRI  as  a  substitute  for  biopsy:  the  negative
predictive  value  of  MRI  for  detecting  signiﬁcant
cancers  is  >  90%.  The  absence  of  an  initial  suspect
lesion  or  of  such  a  lesion  in  the  course  of  monitoring
patients  under  active  surveillance  would  mean
biopsy  would  be  avoided.
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Rlinical case
his  patient,  aged  64,  consulted  owing  to  an  increase  in  PSA
o  6.61,  whereas  it  was  3.64  three  years  ago.  The  prostate
s  not  suspect  on  DRE.
uestions
.  What  is  the  procedure  to  follow?
.  What  MRI  sequences  should  be  systematically  performed
n  the  prostate?
.  What  biopsy  protocol  should  be  applied?
.  What  is  the  risk  of  not  performing  MRI,  or  of  not  perform-
ng  targeted  biopsy  of  an  abnormality  seen  in  an  MRI?
nswers
.  A  series  of  prostate  biopsies  preceded  by  MRI.  Multipara-
etric  MRI  is  performed  before  the  prostate  biopsies  using
.5  T  equipment  with  a  pelvic  coil.
.  The  protocol  for  the  prostate  should  systematically
nclude  three  types  of  sequence:  T2-weighted  axial  and
oronal  sequences,  diffusion  and  perfusion  sequences
acquired  every  10  to  15  seconds,  with  subtraction).
.  Twelve  systematic  biopsies  must  be  taken,  as  well  as
wo  biopsies  targeted  on  the  very  suspect  right  transition
rea,  with  an  anteroposterior  axis  in  MRI  of  12  mm  (Fig.  2).A.  Villers  et  al.
uring  these  prostate  biopsies,  a  suspect  nodule  was
etected  by  ultrasound  in  the  right  peripheral  area.  Two  tar-
eted  biopsies  of  the  suspect  nodule  of  the  right  peripheral
rea  were  therefore  also  taken.  Histopathological  analysis  of
he  biopsy  cores  showed  1  systematic  biopsy  in  12  invaded
or  2  mm  by  an  adenocarcinoma  with  a  Gleason  score  of
 +  3  =  6  in  the  right  lateral  mid  zone.  The  biopsies  targeted
n  the  suspect  area  in  the  MRI  were  both  invaded  for  8  and
 mm  by  an  adenocarcinoma  scoring  3  +  5  =  8.  The  biopsies
argeted  on  the  suspect  nodule  in  the  ultrasound  were  neg-
tive.
.  If  only  systematic  biopsies  had  been  done,  the  patient
ould  have  been  considered  as  having  a  well  differentiated
icrofocus  with  a  low  risk  of  progression  (PSA  <  10  ng/mL)
nd  could  have  been  included  in  a  protocol  of  active  surveil-
ance.  The  biopsies  targeted  on  the  MRI  suspect  areas
elped  class  the  patient  immediately  as  being  at  high  risk
f  progression  and  requiring  curative  treatment  without
elay.
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